- Home
- MVSTW vs SLRX Comparison
MVSTW vs SLRX Comparison
Compare MVSTW & SLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MVSTW | SLRX |
|---|---|---|
| Founded | 2006 | N/A |
| Country | United States | United States |
| Employees | 1921 | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 3.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | MVSTW | SLRX |
|---|---|---|
| Price | $0.13 | $0.66 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 126.0K | ★ 388.9K |
| Earning Date | 03-14-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $370,989,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 39.03 | N/A |
| 52 Week Low | $0.35 | $0.64 |
| 52 Week High | $0.44 | $108.00 |
Technical Indicators
Market Signals| Indicator | MVSTW | SLRX |
|---|---|---|
| Relative Strength Index (RSI) | 38.41 | 25.15 |
| Support Level | $0.10 | $0.64 |
| Resistance Level | $0.15 | $0.72 |
| Average True Range (ATR) | 0.04 | 0.07 |
| MACD | 0.00 | 0.08 |
| Stochastic Oscillator | 27.15 | 7.27 |
Price Performance
Historical ComparisonAbout MVSTW Microvast Holdings Inc.
Microvast Holdings Inc is a technology innovator that designs, develops, and manufactures lithium-ion battery solutions. It is renowned for its cutting-edge cell technology and its vertical integration capabilities which extends from core battery chemistry to battery packs.
About SLRX Salarius Pharmaceuticals Inc.
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.